Aclaris Therapeutics Inc (ACRS) financials
Aclaris Therapeutics revenue and earnings by year
Aclaris Therapeutics's revenue was $7.83 million in the fiscal year to December 31, 2025, down 58.2% from the year before. Net income was -$64.9 million, -829.6% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 21.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 19 | 31 | 30 | 7 | 6 | 4 | 6 | 2 |
| Revenue growth | -58.2% | -40.1% | 5.0% | 340.1% | 4.3% | 53.3% | -31.3% | 265.5% | — |
| Gross profit | 1 | 3 | 13 | 18 | 2 | 1 | 0 | 2 | 0 |
| Gross margin | 6.9% | 17.4% | 42.1% | 59.8% | 30.3% | 20.8% | 4.1% | 29.6% | 28.3% |
| Operating income | -74 | -139 | -124 | -85 | -65 | -49 | -110 | -85 | -54 |
| Operating margin | -946.5% | -744.8% | -397.6% | -286.2% | -967.1% | -748.5% | -2610.0% | -1378.3% | -3230.0% |
| Net income | -65 | -132 | -88 | -87 | -91 | -51 | -161 | -133 | -69 |
| Net margin | -829.6% | -705.5% | -283.1% | -292.1% | -1344.0% | -787.0% | -3817.2% | -2158.0% | -4071.5% |
| Diluted EPS | -$0.53 | -$1.71 | -$1.27 | -$1.33 | -$1.60 | -$1.20 | -$3.90 | -$4.04 | -$2.43 |
| Free cash flow | -47 | -20 | -80 | -68 | -52 | -39 | -98 | -102 | -56 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ACRS in Markets.
How Aclaris Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| License & Service | $1.27M | 78.1% |
| Laboratory Research Revenue | $356K | 21.9% |
See also: ACRS returns
No forecast, no recommendation. This page describes Aclaris Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.